Clinical Trial Update: Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/Phase 2 study of 225Ac-J591 for progressive metastatic castration-resistant prostate cancer, noting the trial is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• 225Ac-J591 (Actinium-225-labeled J591)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING